Maxigen Biotech Inc. AI Stock Analysis
Maxigen Biotech Inc. (1783) AI Stock Analysis
Maxigen Biotech Inc.
(TWSE:1783)
Maxigen Biotech scores well on the strength of outstanding financials — multi-year revenue growth, sector-leading ~70% gross and ~33% net margins, a virtually debt-free balance sheet and consistently positive free cash flow. Valuation reinforces the case, with a modest 9.0x P/E and a 5.76% dividend yield backed by strong cash generation. The main drag is technical: the stock sits below all key moving averages with negative MACD, reflecting a persistent downtrend, though oversold RSI and Stochastic readings suggest the selling may be stretched. Secondary watch items include flat operating cash flow versus rising earnings, higher capex pressuring free cash flow, and the company's small revenue base.
Maxigen Biotech Inc. (1783) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.19B
- Dividend Yield
- 5.67%
- Average Volume (3M)
- 73.69K
- Price to Earnings (P/E)
- 9.2
- Beta (1Y)
- 0.31
- Revenue Growth
- 8.14%
- EPS Growth
- 29.10%
- Country
- TW
- Employees
- 127
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Maxigen Biotech Inc. Business Overview & Revenue Model
Company Description
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Fo...
Maxigen Biotech Inc. Financial Statement Overview
Summary
Exceptional fundamentals for a small-cap medical device maker. Revenue grew from NT$457.7m (2020) to NT$811.6m with a ~19% jump in the latest year, while gross margin expanded to 69.5%, operating margin to 32.2% and net margin to 32.7% — far above sector norms. The balance sheet is near debt-free (debt/equity 0.07, equity funding ~81% of assets) with ROE improving from 7.4% to 17.3%. Cash flow is the softer element: operating cash flow was flat at NT$290.2m despite higher earnings, and free cash flow fell ~22% to NT$207.6m on higher capex, hinting at working-capital build. Small absolute scale and uneven year-to-year growth are the other caveats.
Income Statement
88Very PositiveBalance Sheet
89Very PositiveCash Flow
77Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 837.44M | 811.56M | 680.65M | 622.12M | 604.43M | 511.98M |
| Gross Profit | 585.43M | 563.72M | 483.32M | 424.09M | 373.99M | 261.03M |
| EBITDA | 304.68M | 293.18M | 221.40M | 177.09M | 195.43M | 130.56M |
| Net Income | 291.20M | 265.31M | 190.17M | 165.83M | 139.40M | 87.67M |
Balance Sheet | ||||||
| Total Assets | 2.03B | 1.89B | 1.58B | 1.49B | 1.45B | 1.27B |
| Cash, Cash Equivalents and Short-Term Investments | 997.26M | 877.69M | 640.55M | 432.58M | 801.26M | 540.18M |
| Total Debt | 102.25M | 101.40M | 0 | 50.00K | 0 | 9.74M |
| Total Liabilities | 534.02M | 355.54M | 207.36M | 131.88M | 152.07M | 123.47M |
| Stockholders Equity | 1.50B | 1.54B | 1.38B | 1.36B | 1.30B | 1.14B |
Cash Flow | ||||||
| Free Cash Flow | 241.33M | 207.59M | 266.45M | 148.76M | 253.90M | 102.15M |
| Operating Cash Flow | 332.49M | 290.22M | 298.22M | 171.20M | 268.34M | 117.59M |
| Investing Cash Flow | -338.04M | -382.99M | -29.07M | -490.25M | 10.43M | -2.77M |
| Financing Cash Flow | 24.82M | 30.66M | -59.73M | -41.39M | -1.05M | 188.69M |
Maxigen Biotech Inc. Peers Comparison
Overall Rating
- TW:178376Outperform
TW:673346Neutral
TW:646142Neutral
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1783 | 76Outperform | TWD 3.16B | 9.18 | ― | 5.67% | 8.14% | 29.10% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6733 | 46Neutral | TWD 2.80B | -38.91 | ― | ― | 10.74% | 21.61% |
| TW:6461 | 42Neutral | TWD 2.94B | -5.89 | ― | ― | -57.87% | -21.67% |
| TW:6875 | 37Underperform | TWD 3.24B | -9.12 | ― | ― | -69.26% | -24.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1783 | Maxigen Biotech Inc. | 35.25 | -7.29 | -17.13% | |
| TW:4178 | Stemcyte International Ltd. | 15.95 | -6.45 | -28.79% | |
| TW:6461 | Intech Biopharm Ltd | 26.55 | 1.66 | 6.65% | |
| TW:6733 | BioGend Therapeutics Co., Ltd. | 20.85 | -18.33 | -46.78% | |
| TW:6875 | Pharmosa Biopharm Inc. | 25.05 | -24.60 | -49.55% | |
| TW:7427 | Great Novel Therapeutics Biotech & Medicals Corp. | 59.50 | 21.41 | 56.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026